脱氧胞苷激酶 同义词: deoxycytidine kinase; deoxynucleoside kinase
圣克鲁斯生物技术
| 小鼠 单克隆（2243C2） | | 圣克鲁斯生物技术脱氧胞苷激酶抗体（SantaCruz, 2243C2)被用于被用于流式细胞仪在人类样品上 (图 1b). Onco Targets Ther (2017) ncbi |
| 小鼠 单克隆（H-3） | | 圣克鲁斯生物技术脱氧胞苷激酶抗体（Santa, sc-393099)被用于被用于免疫印迹在人类样品上浓度为1:500 (图 3a). Nat Med (2017) ncbi |
| 小鼠 单克隆（H-3） | | 圣克鲁斯生物技术脱氧胞苷激酶抗体（Santa Cruz Biotechnology, sc-393099)被用于被用于免疫印迹在人类样品上 (图 4). Nat Commun (2016) ncbi |
| 小鼠 单克隆（2243C2） | | 圣克鲁斯生物技术脱氧胞苷激酶抗体（SantaCruz, 2243C2)被用于被用于免疫印迹在人类样品上浓度为1:500 (图 2a). Oncotarget (2016) ncbi |
| 小鼠 单克隆（2243C2） | | 圣克鲁斯生物技术脱氧胞苷激酶抗体（santa Cruz, sc-81245)被用于被用于免疫印迹在人类样品上浓度为1:200 (图 3). PLoS ONE (2015) ncbi |
北京傲锐东源
| 小鼠 单克隆（OTI16G6） | | 北京傲锐东源脱氧胞苷激酶抗体（OriGene, 16G6)被用于被用于免疫组化-石蜡切片在人类样品上 (图 1). Acta Oncol (2016) ncbi |
艾博抗（上海）贸易有限公司
| 兔 多克隆 | | 艾博抗（上海）贸易有限公司脱氧胞苷激酶抗体（Abcam, ab151966)被用于被用于免疫印迹在人类样品上浓度为1:1000. Oncol Rep (2015) ncbi |
| 兔 多克隆 | - 免疫印迹; 小鼠
- 免疫组化-石蜡切片; 人类; 1:100
- 免疫印迹; 人类
| 艾博抗（上海）贸易有限公司脱氧胞苷激酶抗体（Abcam, ab96599)被用于被用于免疫印迹在小鼠样品上, 被用于免疫组化-石蜡切片在人类样品上浓度为1:100 和 被用于免疫印迹在人类样品上. Clin Cancer Res (2014) ncbi |
LifeSpan Biosciences
| 兔 多克隆 | | LifeSpan Biosciences脱氧胞苷激酶抗体（Lifespan Biosciences, LS-B1825)被用于被用于免疫组化-石蜡切片在人类样品上浓度为1:200. Anticancer Res (2012) ncbi |
Townsend M, Anderson M, Weagel E, Velazquez E, Weber K, Robison R,
et al. Non-small-cell lung cancer cell lines A549 and NCI-H460 express hypoxanthine guanine phosphoribosyltransferase on the plasma membrane. Onco Targets Ther. 2017;10:1921-1932
pubmed 出版商 Schneider C, Oellerich T, Baldauf H, Schwarz S, Thomas D, Flick R,
et al. SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia. Nat Med. 2017;23:250-255
pubmed 出版商 Almqvist H, Axelsson H, Jafari R, Dan C, Mateus A, Haraldsson M,
et al. CETSA screening identifies known and novel thymidylate synthase inhibitors and slow intracellular activation of 5-fluorouracil. Nat Commun. 2016;7:11040
pubmed 出版商 Huang Y, Peng W, Furuuchi N, DuHadaway J, Jimbo M, Pirritano A,
et al. Insights from HuR biology point to potential improvement for second-line ovarian cancer therapy. Oncotarget. 2016;7:21812-24
pubmed 出版商 Elebro J, Ben Dror L, Heby M, Nodin B, Jirström K, Eberhard J. Prognostic effect of hENT1, dCK and HuR expression by morphological type in periampullary adenocarcinoma, including pancreatic cancer. Acta Oncol. 2016;55:286-96
pubmed 出版商 Lorkova L, Scigelova M, Arrey T, Vit O, Pospisilova J, Doktorova E,
et al. Detailed Functional and Proteomic Characterization of Fludarabine Resistance in Mantle Cell Lymphoma Cells. PLoS ONE. 2015;10:e0135314
pubmed 出版商 Wang C, Zhang W, Fu M, Yang A, Huang H, Xie J. Establishment of human pancreatic cancer gemcitabine‑resistant cell line with ribonucleotide reductase overexpression. Oncol Rep. 2015;33:383-90
pubmed 出版商 Kerr M, Scott H, Groselj B, Stratford M, Karaszi K, Sharma N,
et al. Deoxycytidine kinase expression underpins response to gemcitabine in bladder cancer. Clin Cancer Res. 2014;20:5435-45
pubmed 出版商 Sekine S, Shimada Y, Nagata T, Moriyama M, Omura T, Yoshioka I,
et al. Establishment and characterization of a new human gallbladder carcinoma cell line. Anticancer Res. 2012;32:3211-8
pubmed
